Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.160
-0.160 (-12.12%)
At close: Sep 21, 2026, 4:00 PM EDT
1.160
0.00 (0.00%)
After-hours: Sep 21, 2026, 5:22 PM EDT
Biofrontera Revenue
Biofrontera had revenue of $12.00M in the quarter ending June 30, 2026, with 32.92% growth. This brings the company's revenue in the last twelve months to $46.18M, up 17.83% year-over-year. In the year 2025, Biofrontera had annual revenue of $41.71M with 11.75% growth.
Revenue (ttm)
$46.18M
Revenue Growth
+17.83%
P/S Ratio
0.40
Revenue / Employee
$491,223
Employees
94
Market Cap
17.23M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.71M | 4.38M | 11.75% |
| Dec 31, 2024 | 37.32M | 3.25M | 9.54% |
| Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
| Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
| Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
| Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
| Dec 31, 2019 | 26.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rockwell Medical | 69.39M |
| Aytu BioPharma | 56.60M |
| SCYNEXIS | 19.22M |
| Universe Pharmaceuticals INC | 17.74M |
| InMed Pharmaceuticals | 4.94M |
| China Pharma Holdings | 3.91M |
| TherapeuticsMD | 3.27M |
| Optimi Health | 123.70K |
BFRI News
- 7 days ago - Biofrontera announces FDA approval of Ameluz supplemental new drug application - TheFly
- 7 days ago - Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma - GlobeNewsWire
- 11 days ago - FDA approves label update for Biofrontera’s Ameluz Gel - TheFly
- 5 weeks ago - Biofrontera Earnings Call Transcript: Q2 2026 - Transcripts
- 5 weeks ago - Biofrontera Earnings release: Q2 2026 - Filings
- 5 weeks ago - Biofrontera Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth - GlobeNewsWire
- 6 weeks ago - Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026 - GlobeNewsWire